SYNLOGIC, INC. Net Income (Loss) Allocated to Limited Partners
SYNLOGIC, INC. (SYBX) reported Net Income (Loss) Allocated to Limited Partners of -$5.31 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2017-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NetIncomeLossAllocatedToLimitedPartners · last filed 2017-11-13
- SYNLOGIC, INC. net income (loss) allocated to limited partners for the quarter ending 2016-09-30 was -$5.31M.
| Period end | Net Income (Loss) Allocated to Limited Partners 3 month | Net Income (Loss) Allocated to Limited Partners 9 month |
|---|---|---|
| 2016-09-30 | -$5.31M 10-Q · filed 2017-11-13 | -$14.11M 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |